Vera Therapeutics/$VERA
1D1W1MYTD1Y5YMAX
Capital at risk
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Ticker
- $VERA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 361
- Headquarters
- Brisbane, United States
- Website
- veratx.com
VERA Metrics
BasicAdvanced
$2.5B
-
-$5.89
0.95
-
Price and volume
Market cap
$2.5B
Beta
0.95
52-week high
$56.05
52-week low
$22.72
Average daily volume
2.1M
Financial strength
Current ratio
10.916
Quick ratio
10.411
Long term debt to equity
18.86
Total debt to equity
18.86
Interest coverage (TTM)
-55.18%
Profitability
EBITDA (TTM)
-415.224
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-46.76%
Return on equity (TTM)
-91.75%
Valuation
Price to book
6.23
Price to tangible book (TTM)
6.24
Price to free cash flow (TTM)
-7.094
Free cash flow yield (TTM)
-14.10%
Free cash flow per share (TTM)
-4.973
Growth
Earnings per share change (TTM)
64.06%
3-year earnings per share growth (CAGR)
23.41%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Analyst projections of the future price of Vera Therapeutics stock.
Bulls say / Bears say
FDA granted priority review to the atacicept Biologics License Application, with a PDUFA target action date of July 7, 2026, accelerating the approval timeline toward a potential mid-2026 launch. (Reuters)
ORIGIN Phase 3 trial of atacicept in IgAN met its primary endpoint with statistically significant proteinuria reduction, as presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, reinforcing its clinical efficacy profile. (Reuters)
Vera completed $800 million in equity and debt financings in 2025 and reported $714.6 million in cash, cash equivalents, and marketable securities at year-end, providing runway through potential approval and U.S. commercial launch. (Reuters)
The company’s 2025 net loss of $299.6 million missed analyst expectations, underscoring a steep cash burn before any product revenue. (Reuters)
Otsuka’s injectable IgAN therapy Voyxact received FDA approval on November 25, 2025, marking the first approved treatment in the space and intensifying competition ahead of atacicept’s launch. (Reuters)
Total operating expenses rose to $315.5 million in 2025, up from $167.2 million in 2024, placing further strain on its balance sheet ahead of commercial revenues. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VERA News
AllArticlesVideos
Funds containing VERA
AllGBPUSDEUR
Fund name | Fund size | $VERA weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.72% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.17% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.